Navigation Links
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Date:6/9/2009

fil 2.5 mg, 10 mg, 20 mg, 40 mg or placebo, orally once a day as monotherapy or as add-on therapy to bosentan. The primary endpoint was change from baseline to Week 16 in six-minute walk distance (6MWD)(2). Demographics, clinical data and health-related quality of life data were collected at baseline. Clinical and health-related quality of life data were collected again at weeks eight and sixteen(3).

Tadalafil increased 6MWD in a dose-dependent manner, only the 40 mg dose met the pre-specified level of statistical significance of less than 0.01 (p<0.01). Overall, the placebo-corrected treatment effect was 33m (95 percent confidence-interval, 15m to 50m). In the bosentan-naive group, the treatment effect was 44m (95 percent confidence-interval, 20m to 69m), as compared to 23m (95 percent confidence-interval, -2m to 48m) in patients on background bosentan therapy.

Among secondary objectives, patients administered tadalafil 40 mg showed improvement in time to clinical worsening, as compared to placebo (5 percent for tadalafil 40 mg, versus 16 percent with placebo)(4,5). Additionally, the incidence of clinical worsening was reduced in the 40 mg tadalafil group (p=0.038; relative risk reduction 68 percent less than placebo).

Improvements in the tadalafil 40 mg dose group, compared to placebo, from baseline to Week 16 were observed in six of the eight domains of the SF-36 health survey and for all sections of the EQ-5D questionnaire(6).

The most commonly reported adverse events for tadalafil 40 mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and flushing (13 percent for tadalafil 40 mg, versus 2 percent with placebo)(7,8,9). Most adverse events were reported as mild or moderate and discontinuation rates were similar across all treatment groups(10).

About ADCIRCA


'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Minn. , Sept. 17, 2014  Rebiotix Inc. announced ... the company,s lead product candidate, RBX2660 (microbiota suspension) will be ... IDWeek 2014 conference in Philadelphia from ... be presented during the poster session on Thursday, October 9, ... C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD ...
(Date:9/17/2014)... , September 17, 2014 ... 17536, has shown positive data in a Phase 2a ... neuropathy , Glenmark Pharmaceuticals today ... Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive ... multi-centre, proof of concept study conducted on 138 patients ...
(Date:9/17/2014)... 2014  Members of the physician IT team ... announced today that the enterprise is working with ... sharing capabilities and provide immediate cluster fail over ... addition, the Dicom Systems enterprise imaging solutions will ... to more effectively deliver the right images to ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... CARY, N.C., March 15, 2011 Saffron ... firm providing Natural Intelligence(1) solutions for business and ... leaders to its corporate Advisory Board . ... business-technology acumen, rich global business experience, and broad ...
... XTIO2 INC . (XTI) presented ... XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM , consisting ...  Nano-Facemask . It is the world,s most effective preventive ... air and contact surfaces. The unique nanocoating protects people ...
Cached Medicine Technology:Saffron Technology Adds Seasoned Business Executives to Advisory Board 2Saffron Technology Adds Seasoned Business Executives to Advisory Board 3OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... WASHINGTON -- The U.S. health care system is not ... the end of life and those of their families, ... a new report from the Institute of Medicine. ... approach to end-of-life care that integrates traditional medical care ... sustainable. The committee called for more "advance care ...
Breaking Medicine News(10 mins):Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 2Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 4Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 5
... in Complex Rehab IndustryWILKES-BARRE, Pa., March 11 James ... years of experience, has joined Alliance Seating & ... accredited complex rehab companies. Conwell is an Assistive ... Supplier (CRTS) in Wilkes-Barre, Pa., for ASM ( www.alliance-seating.com ...
... Prevention, Treatment and Care Services for People around ... March 11 Late yesterday the ... Omnibus Appropriations bill for fiscal year 2009. ... last week, contains an appropriation of $900 million ...
... The U.S. Agency for International Development (USAID) ... launched a new program to reduce HIV vulnerability of ... The three-year, $5.1 million project is funded by the ... administered by USAID . A recent release study ...
... of cancer cells and their frequent divisions have their ... cells. Their metabolism runs at full speed and requires ... of iron in the cell lead to the production ... these, the cell inactivates free iron by binding it ...
... Amex: FHC ) today announced that it will ... of the FC2 Female Condom(R) on Thursday, March ... Company announced its receipt of FDA approval for the ... Shareholders and other interested parties may participate in the conference ...
... ROSEMONT, Ill., March 11 /PRNewswire-USNewswire/ -- Orthopaedic surgeon ... of Councilors (BOC) of the American Academy of ... the Venetian Sands Expo Center in Las Vegas. He ... "As Secretary, I will be one of the voices for ...
Cached Medicine News:Health News:Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund 2Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:David Teuscher, MD, Elected Secretary of Academy Board of Councilors 2
5.5 pointed curved blade. Octagonal handle....
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Medicine Products: